New targeted cell and immunotherapies use the natural immune system to precisely destroy cancer cells, unlike traditional chemotherapy. These therapies enhance T-cell recognition of tumor antigens and prevent tumors from escaping the immune system. They are successful in the treatment of melanoma, breast cancer, lymphoma, renal cell carcinoma, unresectable non-resectable lung cancer, prostate and esophageal cancer. Immune checkpoint inhibitors (ICIs), such as ipilimumab, nivolumab or pembrolizumab, have specific indications and up to 45% of cancer patients are suitable for this therapy. CAR-T cells target the CD19 receptor, achieve 50-90% remission in relapsed or refractory forms of ALL and diffuse large B-cell lymphoma. The combination of nivolumab and ipilimumab resulted in a 5-year overall survival of 52% in advanced melanoma. However, these new drugs cause both acute and chronic toxicities, such as enteritis, pneumonitis, hypophysitis, and hepatitis.[1][3]